This year, pharmaceutical stocks continued to rise, the market value of ten pharmaceutical companies more than 100 billion yuan.

Pharmaceutical Network Industry Dynamics: Pharmaceutical stocks have continued to rise this year, Hengrui Pharmaceuticals, Pharmaceutical Mingkang, Changchun High-tech, Huahai Pharmaceuticals and many other pharmaceutical stocks have reached new highsIt is reported that as of July 17, A-shares Hengrui Pharmaceuticals, Changchun High-tech, film, such as 10 pharmaceutical stocks worth more than 100 billion scaleAmong them, Hengrui Pharmaceuticals broke through the 500 billion mark, sitting firm lying in the chair, the total market value of up to 511.305 billion yuanThe closest close lying company was Murray Medical, with a market capitalization of $402.029 billionAs of July 17, the total market value of the drug Mingkang was 232.276 billion yuanAfter the Zhifei creatures, Changchun high-tech also broke through 190 billion, close to the gate at handPharmaceuticals (Picture Source: Pharmaceutical Network) Hengrui Pharmaceuticals: As of July 17, the total market value of 511.305 billion yuan public information shows that Hengrui Pharmaceuticals' main products include anti-tumor drugs, surgical narcotic drugs, special infusions, contrast agents, cardiovascular drugs and many other fieldsHengrui Pharmaceutical innovation drug business, basically formed every year the pace of new drugs approved to marketIn particular, tumor, diabetes, cardiovascular and other major areas, in the domestic counterparts have a leading advantageAccording to the 2019 report, the company last year obtained 2 batches of innovative pharmaceutical preparations, 29 clinical batches, and image of the history of research and development into three stages, namely, me-too, me-better, source innovationStrong investment in research and development in exchange for fruitful, Hengrui Pharmaceuticals in the drug research and development investment is very large, data show that as of the end of 2019, Hengrui Pharmaceuticals has 3,442 research and development personnel, accounting for 14.09% of the total number of employeesMurray Medical: As of July 17, the total market value of 402.029 billion yuan under the outbreak, Meirui Medical bucked the trend to achieve revenue and net profit of the "double pre-growth", the strong performance reflects its own development of a good state, but also a boost to confidence in the entire marketThick and thin hair, The reason why Murray Medical is able to go out to sea quickly, more thanks to the previous accumulation, global layout, local operations, the emergence of technical achievementsIn recent years, Murray Medical has continuously increased its investment in research and development to improve the level of technological innovationAccording to its earnings, the number of Medical Research and Development staff in Murray has grown from 1,764 to 2,508 in 2019At the same time, research and development spending continues to increase, while revenue continues to grow and the proportion of research and development investment has remained at a high level of domestic industry at about 10%Among them, the company's total research and development expenditure in 2019 was RMB1,466 million, up 15.7% YoY In the past 3 years, the average research and development investment of Murray Medical has accounted for nearly 10% Pharmaceutical Mingkang: As of July 17, the total market value of 232.276 billion yuan of pharmaceutical Mingkang as China's large-scale outsourcing services for new drug research and development, since 2018 "back to A", has been favored by the capital market As of July 17, the drug Mingkang with a market value of 232.276 billion yuan ranked in the top three A-share pharmaceutical stocks Data show that in the first half of 2020, the operating income of pharmaceutical Mingkang increased by 22.68 percent year-on-year, and the net profit of the parent company increased by 62.49 percent year-on-year The main business of pharmaceutical Mingkang is engaged in the discovery, research and development and production of small molecule chemical drugs multi-directional, integrated platform services, but also engaged in a small number of macromolecule biopharmaceutical business and medical health technology services and other business Its main products are contract research and development services (CRO services) and contract production/contract production research and development business (CMO/CDMO services) two sectors of services The company's China laboratory and contract research and development (CRO) and production operations (CDMO) resumed full operations in the second quarter, the company said At the same time, with the rapid growth of overseas customer orders, as well as the company's capacity utilization and operating efficiency continue to improve, the company's second quarter operating income achieved strong growth Zhifei Bio: As of July 17, the total market value of 197.680 billion yuan Zhifei bio-products is China's local comprehensive strength of private biovaccine supply and service providers The main business for vaccines, biological products research and development, production and sales, the market is mainly for the second-class vaccine market With social life back to normal, Zhifei Bio's performance in the second quarter of this year is expected to be higher than the first quarter It is reported that Zhifei biological on April 28 this year independently developed the Ika, the generic name of the drug is "recombinant TB bacteria fusion protein (EC)," to obtain the State Drug Administration's registration approval The listing of this product, to solve the application of 100 years of TB bacteria products (PPD, etc.) can not identify the problem of card-mediated seedling vaccination and TB infection, as an in vivo diagnostic products for TB infection diagnosis and clinically assisted diagnosis of tuberculosis, Iika is currently in the national tender Changchun High-tech: As of July 17, the total market value of 190.421 billion yuan Changchun High-tech main business for biopharmaceuticals and traditional Chinese medicine research and development, production and sales, supplemented by real estate development, property management and real estate leasing business After many years of industrial layout and research and development investment, pharmaceutical products cover innovative genetic engineering pharmaceutical, new vaccines, modern Chinese medicine and other pharmaceutical sub-sectors, is the company's main source of performance It is worth mentioning that Changchun High-tech research and development investment in recent years has been maintained at a high level, in 2015, 2016, 2017, 2018 and 2019 Changchun high-tech research and development investment accounted for 8.01%, 9.14%, 8.5%, 7.37%, 5.51%, respectively There is a pay-off, it is in recent years, high eras of research and development investment to make Changchun high-tech research and development to produce competitive products It is reported that in the pharmaceutical industry, Changchun Gaoxin has achieved the chickenpox vaccine leader and growth hormone industry leader, its potential seems to be obvious As of 2019, Changchun High-tech has achieved revenue of 7.374 billion yuan, ranking among the top four in the biologics industry, and this year in the capital market hit a high of 512.88 yuan (forward re-entitlement) since the listing Eyre Ophthalmology: As of July 17, the total market value of 182.180 billion yuan ophthalmology, as the top in the specialty "golden track", attracting such as Gaoyu Capital, Sequoia China, Temasek and other long-line investment funds, but also created nearly 200 billion market value of the Big Mac - Eyre Ophthalmology It is reported that around the eye surgery, optical services, refractive projects and other business, Aer Eye through the "participation-cultivation-acquisition" of the merger and acquisition path, as well as the hierarchical chain model, quickly grew into the world's large-scale ophthalmology services group, the market value in 10 years has increased 30 times Yunnan White Medicine: As of July 17, the four main businesses of Yunnan White Medicine, with a total market value of 133.067 billion yuan, are divided into four major sectors: pharmaceutical, health products, Chinese medicine resources and pharmaceutical logistics For now, pharmaceuticals remain the company's main source of revenue But after years of development, the health products division has become Yunnan white medicine net profit high department Yunnan White Medicine said it will continue to promote the growth of scale and efficiency, but more emphasis on the steady growth of quality, adhere to the strategy of crude extraction, precision investment, lean management, improve operational quality and improve operating cash flow at the operational level, control liabilities at the financial level and ensure the rational allocation of financial resources in the strategic sectors, and promote the company's performance continued and steady growth Kantai Bio: As of July 17, with a total market value of 130.249 billion yuan, Kantai Bio focuses on vaccine research and development and production, and is one of the enterprises with rich domestic vaccine research and development platform At present, the company sold four seedlings, hepatitis B vaccine, 23 price pneumococcal polysaccharides vaccine, Hib vaccine and leprosy duodumins and other 5 products, the first half of this year issued a number of 3.1219 million, 28.1324 million, 5.3605 million, 466.75 million and 5.2895 million In addition, in April this year, Kantai Bio completed a refinancing project, raising a total of 3 billion yuan, to invest in the Minhai Bionew Vaccine International Ization Industrial Base construction project (Phase I) and supplementary working capital It is reported that Kantai Bio, the market value at the end of last year was only 56.644 billion yuan, but only took half a year, in the first half of the year reached 109.052 billion yuan, as of July 17, the total market value reached 130.249 billion yuan As of July 17, the total market value of 110.347 billion yuan piece of the pharmaceutical industry "brave lying on the heavy responsibility, dare to be the first" spirit, from the brand adhere to hundreds of years of artisan spirit With the development of the times, the pharmaceutical industry has always insisted on doing a good job of core products, selected medicinal herbs, follow the traditional technology, to ensure product quality Don't forget the ancient training, with the sincere production of good medicine, to win consumer confidence in the product The film-and-baby medicine industry can go all the way to this day, but also benefit from a generation of pieces of the people have always used the spirit of artisans to do quality of faith The stock has recently been breaking new highs, with a record 10 trading days in the past month As of July 17, the total market value reached 110.347 billion yuan Gan Li Pharmaceuticals: As of July 17, the total market value of 103.307 billion yuan listed at the end of June this year, more than 10 consecutive trading days, as of July 17, the total market value of 103.307 billion yuan It is reported that the listing of two weeks of the company has ushered in a market value of hundreds of billions of yuan, due to the company's main restructuring of insulin analogue raw materials and injections research and development, production and sales, also known in the industry as "the drug Maotai." But the victory was a flash in the pan On July 16th and 17th, the share price experienced two consecutive dips, and by the close of trading on July 21st, Ganli Pharmaceuticals' share price had closed at Rmb212.52, with the company's market value falling to Rmb85.24bn, and its share price had fallen 28.4 per cent for four consecutive days